Alignment Healthcare (NASDAQ:ALHC) COO Sells $274,040.24 in Stock

Alignment Healthcare, Inc. (NASDAQ:ALHC) COO Sebastian Burzacchi sold 15,361 shares of the stock in a transaction on Wednesday, March 18th. The shares were sold at an average price of $17.84, for a total value of $274,040.24. Following the sale, the chief operating officer owned 258,630 shares in the company, valued at approximately $4,613,959.20. This trade represents a 5.61% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link.

Alignment Healthcare Stock Performance

Alignment Healthcare stock opened at $17.34 on Friday. Alignment Healthcare, Inc. has a fifty-two week low of $11.63 and a fifty-two week high of $23.87. The company has a market capitalization of $3.54 billion, a price-to-earnings ratio of -1,732.27, a PEG ratio of 2.54 and a beta of 1.18. The stock has a fifty day moving average of $20.44 and a two-hundred day moving average of $18.80. The company has a debt-to-equity ratio of 1.80, a quick ratio of 1.71 and a current ratio of 1.71.

Alignment Healthcare (NASDAQ:ALHC) last issued its quarterly earnings data on Thursday, February 26th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.15) by $0.10. The business had revenue of $1.01 billion for the quarter, compared to the consensus estimate of $1 billion. Alignment Healthcare had a negative return on equity of 0.49% and a negative net margin of 0.02%.The business’s revenue was up 44.4% on a year-over-year basis. During the same period in the prior year, the business earned ($0.16) earnings per share. On average, analysts anticipate that Alignment Healthcare, Inc. will post -0.69 EPS for the current fiscal year.

Institutional Trading of Alignment Healthcare

Hedge funds have recently added to or reduced their stakes in the business. T. Rowe Price Investment Management Inc. grew its holdings in Alignment Healthcare by 0.6% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 12,643,784 shares of the company’s stock valued at $249,715,000 after buying an additional 79,268 shares during the period. Invesco Ltd. lifted its holdings in shares of Alignment Healthcare by 38.9% during the 4th quarter. Invesco Ltd. now owns 6,202,592 shares of the company’s stock worth $122,501,000 after acquiring an additional 1,735,962 shares during the period. Mercer Global Advisors Inc. ADV lifted its holdings in shares of Alignment Healthcare by 6.9% during the 4th quarter. Mercer Global Advisors Inc. ADV now owns 15,452 shares of the company’s stock worth $305,000 after acquiring an additional 996 shares during the period. Mackenzie Financial Corp boosted its position in shares of Alignment Healthcare by 25.6% in the fourth quarter. Mackenzie Financial Corp now owns 46,917 shares of the company’s stock worth $901,000 after acquiring an additional 9,552 shares during the last quarter. Finally, nVerses Capital LLC acquired a new stake in shares of Alignment Healthcare in the fourth quarter worth approximately $396,000. 86.19% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on the stock. KeyCorp reaffirmed an “overweight” rating and set a $28.00 price target on shares of Alignment Healthcare in a research note on Thursday, January 22nd. Robert W. Baird set a $28.00 price objective on shares of Alignment Healthcare in a research note on Friday, January 30th. Wall Street Zen lowered shares of Alignment Healthcare from a “buy” rating to a “hold” rating in a research report on Saturday, March 7th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Alignment Healthcare in a research note on Wednesday, January 21st. Finally, JPMorgan Chase & Co. boosted their price target on Alignment Healthcare from $23.00 to $26.00 and gave the company an “overweight” rating in a report on Thursday, February 5th. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $24.56.

More Alignment Healthcare News

Here are the key news stories impacting Alignment Healthcare this week:

• Positive Sentiment: Strong fundamentals — Alignment reported Q4 revenue of ~$1.01B and an EPS beat (‑$0.05 vs. consensus ‑$0.15) with revenue up ~44% YoY, which supports longer‑term growth expectations. Earnings Summary
• Positive Sentiment: Analyst bullishness — Multiple brokerages have raised price targets and maintain Buy/Overweight views (e.g., TD Cowen, JPMorgan, KeyCorp, Robert W. Baird), leaving a consensus analyst stance that is constructive for the stock. Analyst Coverage
• Neutral Sentiment: Short‑interest data published for March appears erroneous (shows 0 shares / NaN changes). Do not treat those figures as evidence of new short pressure until exchanges correct the data.
• Neutral Sentiment: High institutional ownership (~86%) can mute volatility from retail flows but also means institutional positioning matters for future moves; a Zacks comparison piece contrasts ALHC with peers for valuation context. BTSG or ALHC: Which Is the Better Value Stock Right Now?
• Negative Sentiment: Secondary offering announced by a major shareholder — the planned secondary raises potential near‑term selling supply and is a clear negative for price action until the offering size and timing are known. Alignment Healthcare announces secondary offering by major shareholder
• Negative Sentiment: Clustered insider selling — several senior executives reported sales on Mar 18–19 (CEO John E. Kao: 73,046 shares; President Dawn Maroney: 36,749; COO Sebastian Burzacchi: 15,361; plus multiple other officers, and Robert Scavo sold 11,285). These simultaneous disposals (~tens of thousands of shares each at ~$17.84) create headline risk and likely contributed to today’s negative sentiment. Representative SEC filings: Kao — Kao SEC Filing, Scavo — Scavo SEC Filing

Alignment Healthcare Company Profile

Alignment Healthcare, Inc (NASDAQ: ALHC) is a health care company specializing in value-based care for Medicare Advantage beneficiaries. The company leverages an integrated care model that combines in-home clinical services, telehealth capabilities and digital health tools to manage chronic conditions, improve outcomes and enhance patient experience.

At the core of Alignment Healthcare’s approach is a proprietary technology platform that aggregates real-time clinical and claims data to support preventive care, risk stratification and personalized care plans.